LIVNLivaNova PLC

LivaNova PLC (NASDAQ: LIVN) | Price: $96.35 | Today's Change: +20.59%

---

What Happened

LivaNova filed its Form 10-Q with the SEC on November 4, 2026, covering results for the third quarter of fiscal year 2026. The filing reveals quarterly revenue of $1.027 billion, reflecting substantial top-line scale for the medical device company. However, despite generating $156.8 million in operating income, the company recorded a net loss of $273.4 million, or -$5.01 per share (basic and diluted), indicating that significant charges — situated below the operating income line — severely impacted the bottom line during the quarter.

Why It Matters

The divergence between a healthy operating income of roughly $157 million and a net loss of over $273 million is the central issue investors must grapple with. This gap of approximately $430 million between operating profit and net income suggests substantial non-operating charges — which could include items such as litigation settlements, impairments, tax charges, or financing costs — though the specific composition of those charges is not detailed in the structured XBRL data provided. The stock's sharp single-day gain of +20.59% to $96.35 suggests the market may have been bracing for a worse outcome, or that additional context in the full filing (such as the nature or non-recurrence of those charges) provided reassurance. Investors should read the full 10-Q filing carefully to understand the precise source of the below-the-line charges.

Analysis

The top-line picture for LivaNova is genuinely constructive: $1.027 billion in quarterly revenue is a meaningful figure for a mid-cap medical device company and points to strong commercial execution across its product portfolio. The operating income of $156.8 million further confirms that the core business is generating real profits before non-operating items intervene.

The critical question — and what the market will now focus on — is whether the charges that produced the $273 million net loss are one-time in nature or recurring. If they are discrete, non-cash, or litigation-related items that are unlikely to repeat, the underlying earnings power of the business looks considerably more attractive than the headline loss implies. If, conversely, the charges reflect ongoing financial obligations (such as structured legal settlements payable over multiple periods or high interest costs), the pressure on reported earnings could persist.

Key items to watch:

• The specific nature and size of non-operating charges disclosed in the full 10-Q narrative
• Whether management provides updated full-year guidance reflecting these charges
• Cash flow from operations, which will offer a cleaner view of business health independent of non-cash items
• Any commentary on litigation exposure, particularly given LivaNova's history with HVAD-related legal matters

The revenue comparison with the $733.9 million figure from Q3 FY2018 (also present in the XBRL data) underscores how substantially the company has grown its top line over approximately eight years — a compounded expansion that speaks to durable commercial momentum.

---

Disclaimer

This report is a news and informational summary based on data extracted directly from LivaNova's SEC filing and is provided for informational purposes only. It does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any investment decision. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions. Past performance is not indicative of future results.

Source

Filed with the SEC on 2026-11-04. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000115/livn-20260930.htm